Aim The threats of novel coronavirus disease 2019 (COVID‐19) have caused fears worldwide. The Fear of COVID‐19 Scale (FCV‐19S) was recently developed to assess the fear of COVID‐19. Although many studies found that the FCV‐19S is psychometrically sound, it is unclear whether the FCV‐19S is invariant across countries. The present study aimed to examine the measurement invariance of the FCV‐19S across eleven countries. Design Cross‐sectional study. Methods Using data collected from prior research on Bangladesh (N = 8,550), United Kingdom (N = 344), Brazil (N = 1,843), Taiwan (N = 539), Italy (N = 249), New Zealand (N = 317), Iran (N = 717), Cuba (N = 772), Pakistan (N = 937), Japan (N = 1,079) and France (N = 316), comprising a total 15,663 participants, the present study used the multigroup confirmatory factor analysis (CFA) and Rasch differential item functioning (DIF) to examine the measurement invariance of the FCV‐19S across country, gender and age (children aged below 18 years, young to middle‐aged adults aged between 18 and 60 years, and older people aged above 60 years). Results The unidimensional structure of the FCV‐19S was confirmed. Multigroup CFA showed that FCV‐19S was partially invariant across country and fully invariant across gender and age. DIF findings were consistent with the findings from multigroup CFA. Many DIF items were displayed for country, few DIF items were displayed for age, and no DIF items were displayed for gender. Conclusion Based on the results of the present study, the FCV‐19S is a good psychometric instrument to assess fear of COVID‐19 during the pandemic period. Moreover, the use of FCV‐19S is supported in at least ten countries with satisfactory psychometric properties.

Ransing et al. (2020) recently summarized the current available instruments for assessing mental health issues relating to the COVID-19 pandemic in Brain, Behavior, and Immunity. Among the four instruments reviewed by Ransing et al. (2020) was the Fear of COVID-19 Scale (FCV-19S) that we co-developed and rated as having the most evidence in relation to its psychometric properties. While the Coronavirus Anxiety Scale (CAS) (Lee, 2020) and the Obsession with COVID-19 Scale (OCS) (Lee, 2020) both have versions in other languages, only their English versions have been psychometrically validated. Moreover, the COVID Stress Scale (CSS) (Taylor et al., 2020) has only been validated in English. However, the FCV-19S, as reviewed by Ransing et al. (2020), has been translated into different language versions and tested in different country populations. Ransing et al. (2020) recommend that there is a need to translate, validate, and cultural-adapt the existing instruments. We would like to point out that the FCV-19S has already been validated in many languages with good psychometric properties in

Background Adhesive capsulitis (AC) of the shoulder is a common disorder that painfully reduces the shoulder range of motion (ROM) among middle-aged individuals. Although physical therapy with home-based exercises is widely advised to restore ROM in the treatment of AC, clinical results vary owing to inconsistent patient compliance. Objective In this study, we aimed to verify the feasibility of a treatment model that involves applying a wearable motion sensor device to assist patients conduct home-based exercises to improve training compliance and the accuracy of exercises, with the ultimate goal of improving the functional recovery of patients with AC. Methods The motion sensor device was comprised of inertial measurement unit–based sensors and mobile apps for patients and physicians, offering shoulder mobility tracing, home-based exercise support, and progress monitoring. The interrater reliability of shoulder mobility measurement using the motion sensor device on 10 healthy participants and 15 patients with AC was obtained using an intraclass correlation coefficient analysis and compared with the assessments performed by two highly experienced physicians. A pilot prospective control trial was then carried out to allocate the 15 patients with AC to two groups: home-based exercise group and motion sensor–assisted rehabilitation group. Changes in active and passive shoulder ROM, pain and functional scores, and exercise completion rates were compared between the groups during a treatment period of 3 months. Results Shoulder ROM, as measured using the motion sensor device, exhibited good to excellent reliability based on the comparison with the measurements of two physicians (intraclass correlation coefficient range, 0.771 to 0.979). Compared with patients with AC in the home-based exercise group, those in the motion sensor–assisted rehabilitation group exhibited better shoulder mobility and functional recovery and a higher exercise completion rate during and after 3 months of rehabilitation. Conclusions Motion sensor device–assisted home-based rehabilitation for the treatment of AC is a useful treatment model for telerehabilitation that enhances the compliance of patients through training, thus improving functional recovery. This helps overcome important obstacles in physiotherapy at home by providing comprehensible and easily accessible exercise instructions, enhancing compliance, ensuring the correctness of exercise, and monitoring the progress of patients.